Clinical Trial Update: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating nivolumab in combination with Radium-223 in men with metastatic castration-resistant prostate cancer; the trial is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING